Diego Cadavid

Chief Medical Officer at X4 Pharmaceuticals


Diego Cadavid, MD, joined the X4 team as Chief Medical Officer in December 2020. He brings more than 22 years of experience in drug development and academic research to X4, having led multiple programs through all phases of clinical development, including small molecules and biologics for the treatment of rare and immunological diseases. Most recently, Dr. Cadavid served as Senior Vice President and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases, including facioscapulohumeral muscular dystrophy, sickle cell disease and beta-thalassemia. Prior to Fulcrum, Dr. Cadavid held several leadership positions at Biogen over an eight-year tenure, including Senior Medical Director of the multiple sclerosis clinical development group. While at Biogen, he also worked as a consultant at the center for immunology and inflammatory diseases at Massachusetts General Hospital (MGH). Previously, Dr. Cadavid was a faculty member at Rutgers-New Jersey Medical School for over 9 years. Dr. Cadavid holds an MD in medicine and surgery from the Pontificia Universidad Javeriana in Bogotá, Colombia, and completed post-doctoral training in microbiology and immunology at the University of Texas Health Science Center in San Antonio, Texas (UTHSCSA). He completed a clinical neurology residency at Georgetown University and conducted a fellowship in neuropathology at Armed Forces Institute of Pathology, both in Washington, DC. He is board-certified and a U.S. licensed clinical neurologist. Dr. Cadavid has published more than 100 peer review publications, review papers, and book chapters.



  • Chief Medical Officer

    Current role

View in org chart